AVANTGEN, INC.

Basic Information

AVANTGEN, INC.
10151 Pacific Mesa Blvd.
SAN DIEGO, CA, 92129-4571

Company Profile

n/a

Additional Details

Field Value
DUNS: 186489899
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Discovery of novel Alzheimer's Disease-specific antigens/epitopes and their captu

    Amount: $224,528.00

    DESCRIPTION (provided by applicant): Since substantial neuronal loss has already occurred by the time Alzheimer's Disease (AD) manifests clinically, considerable research has been directed toward ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Novel platform for isolation of rabbit monoclonal antibodies against modified RNA bases

    Amount: $188,104.00

    DESCRIPTION (provided by applicant): RNA editing and post-transcriptional modification is emerging as a key epigenetic mechanism for fine tuning genetic diversity and RNA function of particular import ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Development of an Intraoral Optical Probe for the Microscopic Evaluation of Denta

    Amount: $224,957.00

    DESCRIPTION (provided by applicant): The development of addiction involves the dopaminergic reward pathway and downstream negative changes that lead to craving and repeat self-administration. While it ...

    SBIR Phase I 2013 Department of Health and Human Services
  4. TOPIC 319 PHASE I; RECOMBINANT RABBIT MONOCLONAL ANTIBODIES AS AFFINITY CAPTURES

    Amount: $199,987.00

    Recombinant rabbit monoclonal antibodies as affinity captures for peptides PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2013 Department of Health and Human Services
  5. IGF::OT::IGF OTHER FUNCTIONS SBIR PHASE II, TOPIC 288, RECOMBINANT ANTIBODIES AS AFFINITY CAPTURES

    Amount: $747,441.00

    The objective of this proposed project is to develop recombinant antibodies against 75 cancer-related proteins. In the Phase I study, we have demonstrated that multiple antibody clones could be isolat ...

    SBIR Phase II 2012 Department of Health and Human Services
  6. OTHER FUNCTIONS- RECOMBINANT ANTIBODIES AS AFFINITY CAPTURES

    Amount: $990,779.00

    One of the biggest roadblocks to the translation of basic proteomic discoveries to potential clinical applications is the lack of robust and sensitive reagents that can capture a given protein reprodu ...

    SBIR Phase II 2012 Department of Health and Human Services
  7. A novel approach for developing GPCR subtype specific antibodies

    Amount: $697,427.00

    DESCRIPTION (provided by applicant): Despite the prevalence of serious mental illness, our current understanding of the pathophysiology of mental disorders is limited. In part, this is due to the comp ...

    SBIR Phase I 2011 Department of Health and Human Services
  8. RECOMBINANT ANTIBODIES AS AFFINITY CAPTURES

    Amount: $149,951.00

    Not Available

    SBIR Phase I 2010 Department of Health and Human Services
  9. DEVELOPMENT OF ALTERNATIVE AFFINITY CAPTURE REAGENTS FOR CANCE

    Amount: $150,000.00

    With the advances in proteomics, thousands of cancer biomarker candidates have been discovered. To fully validate these candidate cancer markers and eventually translate them into clinical use, it is ...

    SBIR Phase I 2010 Department of Health and Human Services
  10. Endothelial Lipase: a novel therapeutic target for HDL and atherosclerosis

    Amount: $277,115.00

    DESCRIPTION (provided by applicant): There is mounting evidence indicating that endothelial lipase (EL) plays a key role in the regulation of circulating cholesterol levels by modulating high-density ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government